Source: http://www.ptab.us/2011/07/reversed-1735-ex-parte-ozkan-et-al.html
Timestamp: 2019-04-24 14:12:31+00:00

Document:
When all other rejections on appeal have been reversed, and the only remaining rejection is a provisional non-statutory obviousness-type double patenting rejection, it is premature to address the provisional rejection. Ex Parte Moncla, 95 USPQ2d 1884, 1885 (BPAI 2010) (precedential).
“[E]ach claim does not necessarily cover every feature disclosed in the specification. When the claim addresses only some of the features disclosed in the specification, it is improper to limit the claim to other, unclaimed features.” Broadcom Corp. v. Qualcomm Inc., 543 F.3d 683, 689 (Fed. Cir. 2008) (quoting Ventana Med. Sys., Inc. v. Biogenex Labs., Inc., 473 F.3d 1173, 1181 (Fed. Cir. 2006)); see also, Martek Biosciences Corp. v. Nutrinova, Inc., 579 F.3d 1363, 1381 (Fed. Cir. 2009) (“[E]ven where a patent describes only a single embodiment, claims will not be read restrictively unless the patentee has demonstrated a clear intention to limit the claim scope using words of expressions of manifest exclusion or restriction.”). Substantive differences between the claims “can be a ‘useful guide in understanding the meaning of particular claim terms.’” Arlington Industries, Inc. v. Bridgeport Fittings, Inc. 632 F.3d 1246, 1254 (Fed. Cir. 2011) (quoting Phillips v. AWH Corp., 415 F.3d 1303, 1314 (Fed. Cir. 2005); see also, Curtiss-Wright Flow Control Corp. v. Velan, Inc., 438 F.3d 1374, 1381 (Fed. Cir. 2006) (“[C]laim differentiation takes on relevance in the context of a claim construction that would render additional, or different, language in another independent claim superfluous.”).
First, Appellants are not entitled to patent a known product by simply attaching a set of instructions to that product. In re Ngai, 367 F.3d 1336, 1339 (Fed. Cir. 2004); See also, King Pharms., Inc. v. Eon Labs, Inc., 616 F.3d 1267, 1278 (Fed. Cir. 2010).

References: v. 
 v. 
 v. 
 v. 
 v. 
 v. 
 v.